New diabetes drug shows promise in Year-Long trial
NCT ID NCT01387737
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new medication, TA-7284, in 1,299 adults with type 2 diabetes over 52 weeks. The goal was to see if the drug is safe and helps control blood sugar when used alone or with other diabetes medicines. Results focused on side effects, blood sugar levels, and weight changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
1,299 people
The number who actually took part.
- Start date
-
May 2011
- Finished
-
Dec 2012
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
20 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Men or women age ≥20 years old * Diagnosed with Type 2 diabetes mellitus at least 3 months before screening * HbA1c of ≥7.0% and ≤10.0% (monotherapy group) * HbA1c of ≥7.0% and ≤10.5% (combination therapy group) Exclusion Criteria: * Type I diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, secondary diabetes mellitus * Past or current history of severe diabetic complications * Fasting plasma glucose \> 270 mg/dL before treatment start * History of hereditary glucose-galactose malabsorption or primary renal glucosuria * Patients requiring insulin therapy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Type 2 diabetes mellitus are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research site
Chugoku, Japan
-
Research site
Hokkaido, Japan
-
Research site
Kanto, Japan
-
Research site
Kinki, Japan
-
Research site
Kyushu, Japan
-
Research site
Shikoku, Japan
-
Research site
Tōhoku, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heartbeat test aims to catch hidden nerve damage in diabetes
- Can Home-Delivered meals help control diabetes?
- New pill takes aim at stubborn blood sugar
- Gene therapy shots aim to save legs from amputation in diabetes
- New pill takes aim at blood sugar in diabetes
- Can AI-Tailored heat warnings shield chronic disease patients from dangerous temperatures?